BRIEF published on 11/20/2024 at 15:35, 2 days 19 hours ago Symrise AG Unveils Strategic Growth Plans at Capital Market Day Sustainability Goals Digitalization Growth Outlook Capital Market Day Symrise Strategy
PRESS RELEASE published on 11/20/2024 at 15:30, 2 days 19 hours ago Symrise Capital Market Day: Unleashing the full beauty of ONE Symrise, being and staying unique Symrise AG hosts successful Capital Market Day unveiling ONE Symrise strategy for sustainable growth and enhanced profitability under new CEO Jean-Yves Parisot Profitability Sustainable Growth Symrise AG Capital Market Day ONE Symrise
BRIEF published on 10/24/2024 at 07:35, 30 days 3 hours ago Symrise Reports Continued Profitable Growth in 2024 Profitable Growth Regional Growth Organic Sales Increase Taste & Nutrition Scent & Care
PRESS RELEASE published on 10/24/2024 at 07:30, 30 days 3 hours ago Symrise continues strong profitable growth course Symrise AG reports 11.1% organic sales growth in first nine months of 2024, reaffirms 7% organic sales target for full year Business Development Organic Sales Growth Profitable Growth Symrise AG 2024 Financial Results
BRIEF published on 09/12/2024 at 14:08, 2 months 10 days ago Executive Board of Symrise AG Reorganized Leadership Changes Executive Board Symrise AG Walter Ribeiro Jörn Andreas
PRESS RELEASE published on 09/12/2024 at 14:03, 2 months 10 days ago Executive Board of Symrise AG reorganized Symrise AG reorganizes Executive Board with Walter Ribeiro appointed for Taste, Nutrition & Health. Jörn Andreas leaves. Jean-Yves Parisot interim head of Scent & Care segment Executive Board Reorganization Symrise AG Walter Ribeiro Jörn Andreas
BRIEF published on 08/01/2024 at 07:35, 3 months 22 days ago Symrise Reports Q1 2024 Profitable Growth Despite Global Challenges Financial Results EBITDA Margin Organic Sales Growth Profitable Growth Symrise AG
PRESS RELEASE published on 08/01/2024 at 07:30, 3 months 22 days ago Symrise on a profitable growth course in a challenging environment Symrise AG reports 6.3% sales increase and higher profitability in H1 2024. Targets 5-7% organic growth in 2024 with 20% EBITDA margin Profitability EBITDA Margin Sales Increase Growth Targets Symrise AG
BRIEF published on 04/25/2024 at 07:35, 6 months 28 days ago Symrise Reports Strong Start to 2024 with Enhanced Sales and Growth Projections Organic Sales Growth Symrise AG 2024 Financial Growth Scent And Care Division EBITDA Targets
PRESS RELEASE published on 04/25/2024 at 07:30, 6 months 28 days ago Symrise sees successful start into the 2024 fiscal year Symrise AG reports successful start in 2024 fiscal year with 10.9% organic growth and €1.3 billion in group sales for Q1. Targets through 2028 confirmed Organic Growth Sales Increase Symrise AG 2024 Fiscal Year Long-term Targets
Published on 11/22/2024 at 23:55, 10 hours 41 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 11 hours 6 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 11 hours 31 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 12 hours 6 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 16 hours 21 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 16 hours 42 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 17 hours 40 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 18 hours 35 minutes ago Proposed cancellation of admission to trading
Published on 11/21/2024 at 06:58, 2 days 3 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 15 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 16 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 16 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
